Bal S et al. Multiple myeloma with t(11;14) unique biology and evolving landscape. Am J Cancer Res 2022;12(7):2950-65. Abstract
Bal S et al. Treatment outcomes of triple class refractory multiple myeloma: A benchmark for new therapies. Leukemia 2022;36(3):877-80. Abstract
Bansal R et al. Extramedullary disease in multiple myeloma. Blood Cancer J 2021;11(9):161. Abstract
Baughn LB et al. Current testing practices for t(11;14) rearrangements in patients with newly diagnosed multiple myeloma in the United States. ASH 2022;Abstract 4544.
Chari A et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 results from MonumenTAL-1. ASH 2022;Abstract 157.
Claveau J-S et al. Current role of allogeneic stem cell transplantation in multiple myeloma. Oncol Ther 2022;10(1):105-22. Abstract
Costa LJ et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv 2021;5(19):3748-59. Abstract
Davies FE et al. Perspectives on the risk-stratified treatment of multiple myeloma. Blood Cancer Discov 2022;3(4):273-84. Abstract
Emechebe N et al. Real-world effectiveness of bortezomib plus dexamethasone in patients with t(11;14) positive multiple myeloma. ASH 2021;Abstract 4725.
Goel U et al. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol 2022;97(Suppl 1):S3-25. Abstract
Goldman-Mazur S et al. Second- and third-line treatment strategies in multiple myeloma: A referral-center experience. Blood Cancer J 2022;12(12):164. Abstract
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Karam D, Kumar S. Post-transplant maintenance treatment options in multiple myeloma. Oncol Ther 2021;9(1):69-88. Abstract
Kumar S. Multiple myeloma: From baby steps to giant strides. JCO Oncol Pract 2021;17(7):419-20. Abstract
Kumar SK et al. Fixed duration daratumumab, ixazomib, lenalidomide, and dexamethasone quadruplet for newly diagnosed multiple myeloma – MRD negativity and survival outcomes. ASH 2022;Abstract 4556.
Kumar SK et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma — Results of the Ascent trial. ASH 2022;Abstract 757.
Kumar SK et al. MonumenTAL-5: A phase 3 study of talquetamab versus belantamab mafodotin in patients with relapsed/refractory multiple myeloma who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an Anti-CD38 monoclonal antibody. ASH 2022;Abstract 3243.
Mateos M-V et al. MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. ASCO 2022;Abstract TPS8072.
Mohan M et al. Immunotherapy in multiple myeloma—Time for a second paradigm shift. JCO Oncol Pract 2021;17(7):405-13. Abstract
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract
Nooka AK et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. ASCO 2022;Abstract 8007.
Rajkumar SV et al. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J 2022;12(9):129. Abstract
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. ASCO 2022;Abstract LBA4.
Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract
Sharon D et al. Clinical genomic analyses demonstrate t(11;14) multiple myeloma retains B-cell biology and distinct mitochondrial metabolism that convey increased sensitivity to BCL-2 inhibition by venetoclax. ASH 2022;Abstract 1847.
Searle E et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: Results from one cohort of MajesTEC-2, a phase 1b, multicohort study. ASH 2022;Abstract 160.
Sidiqi MH et al. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. Am J Hematol 2021;96(9):1131-6. Abstract
Soefje S et al. Assessment of clinical use parameters associated with a switch from intravenous to subcutaneous daratumumab administration in patients with multiple myeloma at Mayo Clinic. EHA 2021;Abstract EP1051.
Soefje S et al. Clinical administration characteristics of subcutaneous and intravenous administration of daratumumab in multiple myeloma patients at mayo clinic. ASH 2021;Abstract 2717.
Voorhees PM et al. Perspectives on drug development in multiple myeloma—looking forward to 2025. Clin Cancer Res 2022;28(1):23-6. Abstract